FastWave Medical Granted Fifth Utility Patent Reflecting Continuous Expansion of IVL IP Portfolio

Minneapolis, Minn. – FastWave Medical, a clinical-stage medical device company developing advanced intravascular lithotripsy (IVL) technology, achieved a significant milestone with the issuance of its fifth utility patent by the United States Patent and Trademark Office (USPTO).

"FastWave's IVL systems have been designed with physician input to deliver meaningful improvements for the management of calcific disease, which is one of the most difficult challenges we face in treating blood flow-limiting vascular blockages," said Dr. Peter Schneider, Professor of Surgery in the Division of Vascular & Endovascular Surgery at University of California San Francisco. "I am excited to witness FastWave's team making tremendous advancements with their IVL technology, supported by a growing IP portfolio."

"This issuance of FastWave's fifth patent from the USPTO marks another milestone for our company and demonstrates clear progress with our unique IVL portfolio," commented Scott Nelson, co-founder and CEO of FastWave Medical. "The FastWave team highly values the collaboration with our medical advisors, translating real-world insights into compelling clinical solutions for the benefit of physicians and their patients."

About FastWave Medical Inc.

FastWave Medical is at the forefront of developing advanced intravascular lithotripsy (IVL) systems for calcific artery disease. With an emphasis on empowering physicians with procedural efficiency, FastWave aspires to redefine the sector by introducing next-generation IVL technologies that elevate the clinician experience and overall patient care. For more insights, please visit https://fastwavemedical.com.